Prima picks up US patent for cancer treatment CVac
Prima BioMed (ASX:PRR) has secured a US patent covering its CVac cancer treatment technology.
The US Patent and Trademark Office (USPTO) has granted Prima’s application for a patent protecting the method of composition and use of CVac.
CVac production involves formulating the treatment using a patient’s own dendritic cells and then reinjecting it into the patient to generate a cytotoxic T cell response against mucin 1, an antigen found on the surface of cancer cells.
The USPTO has also granted a substantial term adjustment for the patent, extending its expiry date until August 2022.
“The grant of this key US patent with a patent term adjustment of almost four years is an important value proposition for Prima,” CEO Marc Voigt commented. “The patent term can potentially be further extended by up to five years if CVac receives market approval before it expires.”
Prima is currently developing CVac in ovarian cancer and recently commenced a phase II trial. CVac is also under development in pancreatic cancer.
The USPTO issued a notice of allowance for the patent application in May. Prima BioMed also has patents covering CVac in Australia, Canada, Europe and Japan.
Prima BioMed (ASX:PRR) shares were trading 10% higher at $0.044 as of around 1 pm on Wednesday.
Could this 'nanobone' material allow children to regrow bone?
Australian scientists believe they have found an alternative to invasive bone graft procedures in...
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
